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Abstract
Background
Conventional surgical risk scores lack accuracy in risk stratification of patients undergoing
transcatheter aortic valve replacement (TAVR).
Elevated levels of midregional proadrenomedullin (MR-proADM) levels are associated
with adverse outcome not only in patients with manifest chronic disease states, but also in
the general population.
Objectives
We investigated the predictive value of MR-proADM for mortality in an unselected contem-
porary TAVR population.
Methods
We prospectively included 153 patients suffering from severe aortic stenosis who under-
went TAVR from September 2013 to August 2014. This population was compared to an
external validation cohort of 205 patients with severe aortic stenosis undergoing TAVR. The
primary endpoint was all cause mortality.
Results
During a median follow-up of 258 days, 17 out of 153 patients who underwent TAVR died
(11%). Patients with MR-proADM levels above the 75th percentile ( 1.3 nmol/l) had higher
mortality (31% vs. 4%, HR 8.9, 95% CI 3.0–26.0, P < 0.01), whereas patients with
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EuroSCORE II scores above the 75th percentile (> 6.8) only showed a trend towards higher
mortality (18% vs. 9%, HR 2.1, 95% CI 0.8–5.6, P = 0.13). The Harrell’s C-statistic was 0.58
(95% CI 0.45–0.82) for the EuroSCORE II, and consideration of baseline MR-proADM lev-
els significantly improved discrimination (AUC = 0.84, 95% CI 0.71–0.92, P = 0.01). In bivar-
iate analysis adjusted for EuroSCORE II, MR-proADM levels1.3 nmol/l persisted as an
independent predictor of mortality (HR 9.9, 95% CI (3.1–31.3), P <0.01) and improved the
model’s net reclassification index (0.89, 95% CI (0.28–1.59). These results were confirmed
in the independent validation cohort.
Conclusions
Our study identified MR-proADM as a novel predictor of mortality in patients undergoing
TAVR. In the future, MR-proADM should be added to the commonly used EuroSCORE II for
better risk stratification of patients suffering from severe aortic stenosis.
Introduction
Transcatheter aortic valve replacement (TAVR) has emerged as a treatment option for patients
with aortic stenosis at prohibitive, high or intermediate surgical risk [1–3]. Although at present
TAVR is performed with a low intra-procedural complication rate and very favorable 30-day
outcome, TAVR-patients still face a high long-term mortality reaching up to 44% at 3 years.
The majority of deaths appear to be related to co-morbidities, rather than procedural complica-
tions, highlighting the importance of optimal risk assessment of patients considered for TAVR
[4–8]. While also lower risk patients are currently evaluated for TAVR, it remains difficult to
identify those that will not benefit from TAVR. Today, the risk-benefit evaluation for TAVR is
mainly done on the basis of clinical judgment and surgical scoring systems such as the Euro-
SCORE II [9]. However, these commonly used risk scores have failed to truly predict long-term
outcome in patients undergoing TAVR [10, 11].
Novel biomarkers may be useful for the prognostication and initiation of tailored therapies
in patients deemed for TAVR. In this regard, the utility of midregional pro-adrenomedullin
(MR-proADM), the midregional precursor of adrenomedullin (ADM) is of interest as it is an
indicator for disease severity in a wide spectrum of cardiovascular disease states as well as vari-
ous non-cardiovascular diseases including sepsis, COPD, pneumonia and chronic renal insuffi-
ciency [12–16]. Physiologically, ADM exhibits natriuretic and vasodilatatory effects, and it is
expressed in different tissues, where it acts both as an autocrine and paracrine mediator [17,
18]. MR-proADM is a prime marker for global hemodynamic stress and cardiovascular dys-
function, and is highly predictive for adverse outcomes in patients with heart failure [19].
Indeed, MR-proADM levels are associated with important cardiovascular risk factors in elderly
patients [20], and predict mortality in the general population [21]. Moreover, in unselected
patients presenting to an emergency department, the MR-proADM plasma levels are elevated
in proportion to disease severity, and possess the unique ability to identify patients at risk for
short-term mortality beyond clinical risk assessment [22].
Whether pre-procedural MR-proADM levels are predictive for outcome in an elderly
patient population undergoing TAVR has not been explored to date. In the present study, we
therefore investigated the utility of pre-procedural MR-proADM for risk stratification of
patients undergoing TAVR beyond the EuroSCORE II.
Proadrenomedullin and Risk Prediction in TAVR
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Materials and Methods
Study population
Patients were eligible for the study if they were accepted by the Heart Team to undergo transfe-
moral TAVR at the University Heart Center Zurich. Patients were recruited between Septem-
ber 2013 and August 2014, after giving written informed consent. Exclusion criteria were
age< 18 years and infections (CRP> 20 mg/L), such as urinary tract infections, endocarditis,
pneumonia or wound infections.
A second cohort of 205 patients derived from the Kerckhoff Heart Center in Bad Nauheim,
Germany served as an external validation sample.
Approval for the current study was obtained from the Ethics Committee of the University
of Zurich, and by the local Ethics committee for the Kerckhoff Heart Center TAVR registry.
An independent critical event committee adjudicated all events of the study cohort.
Measurement of MR-proADM levels
EDTA plasma samples were collected, frozen at the study site at -80°C and shipped to the
Department of Internal Medicine, Kantonsspital Aarau, Switzerland, where the specimens
were subsequently stored at -80°C. Samples were also collected at postoperative days 1–3. Mea-
surement of MR-proADM levels was carried out as described previously [23].
Clinical endpoints
The primary clinical endpoint for this analysis was defined as all-cause mortality. Device success
and early safety were calculated using the VARC-2 definitions (Valve Academic Research Con-
sortium-2) [24]. Procedure-related complications including high-degree AV-block with the need
for pacemaker implantation, and outcome as related to post-procedural changes in the level of
MR-proADM and C-reactive protein (CRP) levels, were assessed as secondary endpoints.
Statistical analyses
Baseline plasmaMR-proADM levels were measured in all 153 patients undergoing TAVR at the
University Heart Center Zuerich. In 121 patients, a complete set of samples at postoperative days
1–3 was available. In the validation cohort, biomarkers were measured at baseline in 205 patients.
Normal distribution was tested using the Kolmogorov-Smirnov test; for variables that signifi-
cantly differed from normality, the Mann-Whitney U test was used. Discrete values are expressed
as counts (percentages), continuous variables as means (SD) or medians (IQR), as appropriate.
Patients were dichotomized at the upper (75th) quartile of baseline levels of MR-proADM. For
modeling the shape function of hazard rates, a flexible Royston-Parmar (RP) regression model
with 3 degress of freedom (dfs) was employed [25]. To account for time-dependent hazard rates,
the grouping variable was included as a time-dependent covariate. To delineate the time course of
biomarkers following TAVR, a linear mixed effects regression model with random intercepts was
employed with determination of an interaction between group and time. External validation of an
RP-derived prediction index (PI) was carried out by application of the PI to the validation cohort,
and comparison of the predicted survival functions with observed mortality (Kaplan Meier esti-
mates). The incremental prognostic utility of MR-proADM to the univariate EuroSCORE II-
derived model was evaluated by calculating the integrated discrimination improvement (IDI) and
the net reclassification improvement (NRI). The discriminative accuracy and model calibration
were assessed by Harrell's C-statistic and the Hosmer-Lemeshow test, respectively. All tests were
two tailed; p< .05 was considered significant. Stata (StataCorp. 2011. Stata Statistical Software:
Release 13. College Station, TX: StataCorp LP) was used for the statistical analyses.
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Results
Baseline characteristics and distribution of MR-proADM levels
Baseline characteristics of the two patient cohorts investigated are shown in Tables 1 and 2,
respectively. In the derivation cohort, both balloon expandable (SAPIEN XT or Sapien 3,
n = 94) or self-expandable prostheses (CoreValve, Medtronic, n = 46) were used; in 13 patients,
an alternative type of valve was used. In the validation cohort, TAVR was performed using bal-
loon expandable (Edwards SAPIEN, n = 53) or self-expandable prostheses (CoreValve, Med-
tronic, n = 119); in 33 patients, an alternative type of valve was used. TAVR was performed via
the transfemoral route in both patient cohorts.
In the derivation cohort, patients had a median age of 82 years (78–86), 50% were male.
Baseline levels of MR-proADM ranged from 0.3 nmol/L to 4.4 nmol/L, with a median of 1.1
nmol/L and 25th and 75th percentile values of 0.8 nmol/L and 1.3 nmol/L, respectively. Median
baseline values of MR-proADM were significantly higher in patients who died during follow-
up, and patients in the upper quartile of MR-proADM also experienced a higher rate of proce-
dural complications in both cohorts of patients (Tables 1–4).
Association between baseline MR-proADM levels and mortality
During a median follow-up of 258 days (IQR 169–443), 17 patients died (11%), whereof 7
patients died within the first 30 postinterventional days and 10 patients died beyond 30 days.
Patients belonging to the upper quartile of MR-proADM ( 1.3 nmol/L) experienced a sig-
nificantly higher rate of death as compared to subjects in quartile 1–3 (31% vs. 4%, HR 8.9, CI
3.0–26.0, P< 0.01), and the association with risk of death was maintained after adjusting for
baseline EuroSCORE II (HR 9.9, 95% CI 3.1–31.3, P< 0.01). If analyzed as a continuous vari-
able and after adjustment for EuroSCORE II, progressively higher MR-proADM values were
associated with increased risk of death (HR 3.3, 95% CI 2.1–5.0, P< 0.01).
Patients who died during follow up had higher EuroSCORE II compared with survivors (3.6
vs. 5.9, P = 0.03). However, EuroSCORE II did not predict death (HR 2.1, 95% CI (0.8–5.6),
P = 0.13 for upper quartile) (Table 5).
As procedural mortality adds to the hazard rate during the early post-interventional phase,
the baseline hazard function peaks early (Fig 1). For EuroSCORE II the AUC was 0.58 (95%
CI, 0.45–0.82), and consideration of baseline MR-proADM levels significantly improved dis-
crimination for mortality (AUC = 0.84 95% CI 0.71–0.92, P = 0.01). Baseline proBNP levels
emerged as marginally significant predictors of mortality in the univariate analysis, but lost sig-
nificance in conjunction with baseline MR-proADM values. Similarly, addition of proBNP to
the EuroSCORE II did not significantly improve discrimination (Table 5).
Relationship between time course of biomarkers and risk of death
A significant increase of MR-proADM levels across all investigated time points was found
(baseline/day1-3: P< 0.01; Fig 2). Similarly, CRP increased markedly during the early post-
interventional period following TAVR (P< 0.01 for baseline/day1-3). MR-proADM showed a
significant interaction between survivors and non-survivors at different time points (Pinteraction
< 0.01 for baseline/day 1–3). The same was true for CRP levels (Pinteraction< 0.01 for baseline/
day 1–3). No interaction was found with type of valve implanted and occurrence of post-inter-
ventional high-degree AV-block making pacemaker implantation necessary (P> 0.05 for all
biomarkers investigated).
Proadrenomedullin and Risk Prediction in TAVR
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External validation cohort
The baseline and procedural characteristics of the external validation cohort are shown in
Tables 3 and 4. During a one-year follow-up, 37 patients died (18%). Baseline MR-proADM
Table 1. Baseline characteristics of the derivation study population according to all-causemortality and upper quartile of MR-proADM.
Variables Total sample
(n = 153)
Survived
(n = 136)
Deceased
(n = 17)
P
Value
Baseline MR-proADM
quartile 1–3 (< 1.3 nmol/
L) (n = 114)
Baseline MR-proADM
quartile 4 ( 1.3 nmol/L)
(n = 39)
P
Value
Clinical characteristics
Age,yrs (median, IQR) 82 (78–86) 82 (77–75) 86 (82–88) 0.03 82 (77–85) 83 (78–88) 0.11
Male sex, n (%) 76 (50) 64 (47) 12 (70) 0.06 59 (52) 17 (44) 0.37
EuroSCORE II (median,
IQR)
3.9 (2.2–6.8) 3.5 (2.0–
6.48)
5.8 (3.3–9.0) 0.03 3.2 (1.9–4.7) 7.9(4.3–12.3) < 0.01
Body mass index, kg/m2
(median, IQR)
27.2 (25–31) 27.2 (25–30) 25.1 (24–32) 0.59 27.2 (25–31) 27.3 (23–32) 0.72
Diabetes, n (%) 42 (28) 36 (27) 6 (35) 0.46 31 (28) 11 (28) 0.95
Hypertension 134 (88) 118 (87) 16 (94) 0.38 102 (90) 32 (82) 0.22
Atrial Fibrillation, n (%) 55 (36) 48 (36) 7 (41) 0.64 34 (30) 21 (54) 0.01
Previous SAVR, n (%) 7 (5) 6 (5) 1 (6) 0.79 4 (4) 3 (8) 0.28
Previous CABG, n (%) 18 (12) 15 (11) 3 (18) 0.43 9 (8) 9 (23) 0.01
Previous CAD, n (%) 81 (52) 68 (50) 13 (76) 0.04 58 (51) 23 (59) 0.40
Previous malignoma, n
(%)
27 (18) 23 (17) 4 (23) 0.50 19 (17) 8 (21) 0.60
Previous MI, n (%) 20 (13) 16 (12) 4 (24) 0.17 13 (12) 7 (18) 0.30
Previous stroke, n (%) 18 (12) 15 (11) 3 (18) 0.43 14 (12) 4 (10) 0.72
Renal failure1, n (%) 90 (59) 76 (56) 14 (82) 0.03 57 (50) 33 (85) <0.01
COPD2, n (%) 22 (15) 18 (13) 4 (25) 0.20 14 (12) 8 (21) 0.18
Peripheral arteriopathy, n
(%)
40 (26) 31 (23) 9 (53) 0.01 28 (25) 12 (31) 0.44
Pacemaker, n (%) 7 (5) 7 (5) 0 (0) 0.33 4 (4) 3 (8) 0.28
NYHA functional class III/
IV, n (%)
106 (70) 94 (70) 12 (71) 0.93 74 (65) 32 (82) 0.05
Laboratory
Hemoglobin, g/dl (mean,
SD)
121 (18.6) 122 (18.2) 112 (20.5) 0.04 124 (18) 110 (16.6) <0.01
MR-proADM, nmol/L
(median, IQR)
1.1 (0.9–1.4) 1.0 (0.9–1.3) 2.1 (1.2–2.5) <0.01
proBNP, ng/l (median,
IQR)
2054 (983–
4972)
1876 (959–
4073)
4506 (1752–
12802)
0.01 1501 (844–2895) 6251 (2274–11015) <0.01
Creatinine,mol/L (median,
IQR)
101 (79–122) 99 (78–116) 140 (104–
165)
0.01 95 (76–109) 124 (105–162) <0.01
Echocardiography
LVEF < 50, n (%) 52 (34) 48 (35) 4 (24) 0.33 34 (30) 18 (46) 0.06
Mean gradient, mmHg
(median, IQR)
42 (31–53) 41 (31–53) 45 (34–51) 0.77 43 (31–53) 37 (30–51) 0.28
Aortic valve area, cm2
(median, IQR)
0.7 (0.6–0.9) 0.7 (0.6–0.9) 0.7 (0.6–0.9) 0.86 0.7 (0.6–0.9) 0.7 (0.6–0.8) 0.36
1GFR<60ml/min.
2Long-term use of bronchodilatators or steroids.
Abbreviations: GFR = glomerular ﬁltration rate, SAVR = surgical aortic valve replacement, CABG = coronary artery bypass grafting, MI = myocardial
infarction, NYHA = New York Heart Association, COPD = chronic obstructive pulmonary disease, BMI = body mass index, CAD = coronary artery disease.
doi:10.1371/journal.pone.0143761.t001
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values ranged from 0.2 nmol/L to 4.3 nmol/L with a median of 0.9 nmol/L and 25th and 75th
percentile values of 0.7 nmol/L and 1.1 nmol/L, respectively. Median MR-proADM levels were
significantly higher in patients who died as compared to survivors (0.9 nmol/L vs. 1.1 nmol/L,
P = 0.01). Belonging to the upper quartile of baseline MR-proADM was significantly associated
with mortality in the univariate analysis (HR 3.9, 95% CI 1.6–5.6, P< 0.01), and after adjusting
for EuroSCORE II (HR 2.7, 95% CI 1.4–5.1, P< 0.01).
Table 2. Baseline characteristics of the external validation population and according to all-causemortality and upper quartile of MR-proADM.
Variables Total sample
(n = 205)
Survived
(n = 168)
Deceased
(n = 37)
P
Value
Baseline MR-proADM
quartile 1–3 (< 1.1 nmol/L)
(n = 152)
Baseline MR-proADM
quartile 4 ( 1.1 nmol/L)
(n = 53)
P
Value
Clinical characteristics
Age,yrs (median, IQR) 83 (80–86) 83 (80–86) 83 (80–87) 0.66 83 (80–86) 83 (80–87) 0.84
Male sex, n (%) 80 (39) 66 (39) 14 (38) 0.87 62 (41) 18 (34) 0.38
EuroSCORE II (median,
IQR)
6.6 (3.4–10.6) 6 (3.3–10.3) 8.4 (4.2–
14.4)
0.04 5.6 (2.9–9.8) 8.2 (5.7–12.6) <0.01
Body mass index, kg/m2
(median, IQR)
27 (24–31) 27 (24–31) 26 (24–31) 0.72 26 (24–30) 30 (27–35) <0.01
Diabetes, n (%) 65 (32) 49 (29) 16 (43) 0.09 39 (26) 26 (49) <0.01
Hypertension 196 (96) 159 (95) 37 (100) 0.15 144 (95) 52 (98) 0.30
Atrial Fibrillation, n (%) 73 (36) 57 (34) 16 (43) 0.28 48 (31) 25 (47) 0.04
Previous SAVR, n (%) 4 (2) 4 (2) 0 0.34 4 (3) 0 0.23
Previous CABG, n (%) 27 (13) 21 (13) 6 (16) 0.54 19 (13) 8 (15) 0.63
Previous CAD, n (%) 124 (60) 102 (61) 22 (60) 0.88 88 (58) 36 (68) 0.19
Previous MI, n (%) 28 (14) 22 (13) 6 (16) 0.61 18 (12) 10 (19) 0.2
Previous stroke, n (%) 29 (14) 24 (14) 5 (14) 0.90 22 (14) 7 (13) 0.82
Renal failure1, n (%) 89 (43) 69 (41) 20 (54) 0.14 52 (34) 37 (70) <0.01
COPD2, n (%) 43 (21) 32 (19) 11 (30) 0.14 36 (24) 7 (13) 0.10
Peripheral arteriopathy, n
(%)
27 (13) 20 (12) 7 (19) 0.25 19 (13) 8 (15) 0.63
Pacemaker, n (%) 23 (11) 16 (10) 7 (19) 0.10 16 (11) 7 (13) 0.59
NYHA functional cIass III/
IV, n (%)
190 (93) 155 (92) 35 (95) 0.62 137 (90) 53 (100) 0.01
Laboratory
Hemoglobin, g/dl (mean,
SD)
124 (14.5) 125.7 (14.2) 115.5 (13.6) 0.01 126.6 (13.2) 116.8 (16) 0.03
MR-proADM, nmol/L
(median, IQR)
0.9 (0.7–1.1) 0.9 (0.7–1.1) 1.1 (0.8–1.9) 0.01
Creatinine, mol/L (median,
IQR)
88 (70.4–
114.4)
88 (70.4–
114.4)
83.6 (70.4–
123.2)
0.90 79.2 (70–105.6) 110 (105.6–140.8) 0.01
Echocardiography
LVEF < 50, n (%) 55 (27) 41 (24) 14 (38) 0.09 35 (23) 20 (37) 0.03
Mean gradient, mmHg
(median, IQR)
43 (34–52) 43 (37–52) 42 (26–50) 0.36 44 (37–52) 41 (26–52.5) 0.16
Aortic valve area, cm2
(median, IQR)
0.6 (0.5–0.7) 0.6 (0.5–0.7) 0.7 (0.5–0.8) 0.12 0.6 (0.5–0.7) 0.7 (0.5–0.8) 0.10
1GFR<60ml/min.
2Long-term use of bronchodilatators or steroids.
Abbreviations: GFR = glomerular ﬁltration rate, SAVR = surgical aortic valve replacement, CABG = coronary artery bypass grafting, MI = myocardial
infarction, NYHA = New York Heart Association, COPD = chronic obstructive pulmonary disease, BMI = body mass index, CAD = coronary artery disease.
doi:10.1371/journal.pone.0143761.t002
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Discrimination, reclassification and validation of risk models
To further establish the additive value MR-proADM levels in conjunction with the Euro-
SCORE II for predicting mortality, we established a univariate (EuroSCORE II) and bivariate
(EuroSCORE II + MR-proADM) model for the binary outcome all-cause mortality, restricting
analysis to patients who completed one-year follow-up. Adding MR-proADM values to the
EuroSCORE II-based equation markedly improved reclassification for one-year mortality.
Likelihood ratio testing confirmed a significantly enhanced model performance of an MR-
proADM-based risk prediction algorithm (Table 6, Fig 3). We moved on to establish a predic-
tion index and categorized the index into two prognostic groups (lower quartiles vs. upper
quartile of predicted risk). While the biomarker-enhanced model enabled wide separation of
Table 4. Procedural complications of the external validation cohort according to all-causemortality and upper quartile of MR-proADM.
Variables Total sample
(n = 205)
Survived
(n = 168)
Deceased
(n = 37)
p
Value
Baseline MR-proADM
quartile 1–3 (<1.1 nmol/L)
(n = 152)
Baseline MR-proADM
quartile 4 ( 1.1 nmol/L)
(n = 53)
p
Value
Device success, n (%) 184 (90) 152 (90) 32 (86) 0.46 138 (91) 46 (87) 0.40
Early Safety, n (%) 188 (92) 168 (100) 20 (54) <0.01 144 (95) 44 (83) <0.01
Myocardial infarction, n (%) 0 0 0 0 0
Emergency sternotomy, n
(%)
6 (3) 5 (3) 1 (3) 0.92 5 (3) 1 (2) 0.60
Major vascular
complications, n (%)
13 (7) 12 (7) 1 (3) 0.31 9 (6) 4 (8) 0.67
Life-threatening bleeding, n
(%)
15 (7) 13 (7) 2 (5) 0.62 13 (9) 2 (4) 0.25
All stroke (disabling and
non-disabling), n (%)
6 (3) 4 (2) 2 (5) 0.32 4 (3) 2 (4) 0.67
Need for pacemaker, n (%) 40 (20) 36 (22) 4 (11) 0.12 26 (17) 14 (26) 0.16
Use of extracorporeal
membrane oxygenation, n
(%)
6 (3) 5 (3) 1 (3) 0.92 5 (3) 1 (2) 0.60
doi:10.1371/journal.pone.0143761.t004
Table 3. Procedural complications of the derivation patient population according to all-causemortality and upper quartile of MR-proADM.
Variables All Patients
(n = 153)
Survived
(n = 136)
Deceased
(n = 17)
P
Value
Baseline MRproADM
quartile 1–3 (< 1.3 nmol/L)
(n = 114)
Baseline MR-proADM
quartile 4 ( 1.3 nmol/L)
(n = 39)
P
Value
Device success, n (%) 146 (95) 135 (99) 11 (65) < 0.01 112 (98) 34 (87) < 0.01
Early safety, n (%) 143 (94) 133 (98) 10 (59) < 0.01 110 (96) 33 (85) 0.01
Myocardial infarction, n (%) 1 (1) 1 (1) 0 0.72 1 (1) 0 0.55
Emergency sternotomy, n
(%)
3 (2) 0 3 (18) < 0.01 0 3 (8) < 0.01
Major vascular
complications, n (%)
3 (2) 0 3 (18) < 0.01 0 3 (8) < 0.01
Life-threatening bleeding, n
(%)
3 (2) 0 3 (18) < 0.01 0 3 (8) < 0.01
All stroke (disabling and
non-disabling), n (%)
2 (1) 1 (1) 1 (6) 0.07 0 (0) 2 (5) 0.01
Need for pacemaker, n (%) 31 (21) 30 (22) 1 (8) 0.22 20 (18) 11 (31) 0.07
Use of extracorporeal
membrane oxygenation, n
(%)
4 (3) 0 4 (24) < 0.01 1 (1) 3 (8) 0.02
doi:10.1371/journal.pone.0143761.t003
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prognoses among the subgroups, the EuroSCORE II-based model performed remarkably poor
with regard to discrimination of patients according to outcome (Fig 4). Finally, we compared
the predicted survival distributions form the derivation cohort with observed (Kaplan Meier)
mortality in the validation cohort and observed reasonably well alignment between both curves
(Fig 5). To further illustrate the diagnostic performance across risk thresholds of the univariate
and bivariate model, we devised risk assessment plots for the reference and biomarker-
enhanced model, and observed wide separation of both the event and nonevent curves between
the models investigated (Fig 6).
Discussion
In the present study we evaluated the ability of MR-proADM to predict outcome in an unse-
lected contemporary cohort of patients undergoing TAVR. We here for the first time report
that higher baseline MR-proADM levels predict mortality following TAVR beyond of the com-
monly used EuroSCORE II, and this finding of the derivation cohort was confirmed in an inde-
pendent validation cohort.
By adding MR-proADM into the equation, discrimination for mortality was markedly
improved. Moreover, considering MR-proADM for risk assessement improved sensitivity and
specificity for the clinical endpoint investigated across the calculated risk thresholds. Conse-
quently, the predictiveness curve of the biomarker-enhanced model shows a much steeper
slope at the high the risk spectrum than the univariate model, and its predictions align signifi-
cantly better with the observed mortality rate as compared to the EuroSCORE II-based model.
Although surgical risk scores consider several comorbidities, in the present study and in line
with clinical experience, its discriminatory power for mortality proved rather modest with an
AUC of 0.58.
Studies on natriuretic peptides were among the first to demonstrate the utility of biomarkers
monitoring the hemodynamic state for risk stratification in patients considered for TAVR [26–
Table 5. RP-proportional hazardsmodel with 3 dfs. Discriminatory ability of biomarker-enhanced models compared to existing risk schemes (Euro-
SCORE II) and proBNP.
Variable Hazard ratio (95% CI) P-Value C-index (95% CI) C-index difference (95% CI, P value)
Univariate
ESII (per 1 unit increase) 1.1 (0.9–1.1) 0.16 0.58 (0.45–0.82)
ES II (uper quartile) 2.1 (0.8–5.6) 0.13
MR-proADM, nmol/L (per 1 unit increase) 3.1 (2.2–4.6) < 0.01 0.84 (0.71–0.92) 0.20 (0.13–0.32, P = 0.01)
MR-proADM (upper quartile) 8.9 (3.0–26.0) < 0.01
proBNP, ng/L (per 1 unit increase) 1.0 (1.0–1.1) 0.03 0.69 (0.60–0.83) 0.11 (-0.09–0.13, P = 0.74)
proBNP (upper quartile) 3.1 (1.2–8.4) 0.02
Bivariate (MR-proADM + ESII)
ESII (per 1 unit increase) 1.0 (0.9–1.1) 0.68
ES II (uper quartile) 0.6 (0.2–2.4) 0.53
MR-proADM, nmol/L (per 1 unit increase) 3.3 (2.1–5.0) < 0.01
MR-proADM (upper quartile) 9.9 (3.2–31.3) < 0.01
Bivariate (MR-proADM + proBNP)
MR-proADM, nmol/L (per 1 unit increase) 6.6 (2.9–14.9) < 0.01
MR-proADM (upper quartile) 6.1 (1.8–19.7) < 0.01
proBNP, ng/L (per 1 unit increase) 0.9 (0.9–1.0) 0.05
proBNP (upper quartile) 1.2 (0.3–4.0) 0.75
doi:10.1371/journal.pone.0143761.t005
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28]. Of note, in the present study, MR-proADM was superior to proBNP in predicting mortal-
ity. In fact, the incremental predictive value of proBNP, when added to the EuroSCORE II,
appeared rather modest, and proBNP lost its predictive value when modeled concomitantly
with MR-proADM. The putative mechanism by which MR-proADM contributes to adverse
outcomes might relate to its role as an unspecific marker of the general health status [21]. More
specifically, its association with overall hemodynamic stress and endothelial dysfunction and
its upregulation by hypoxia, inflammatory cytokines or shear stress may help to explain its role
in the link between heart failure and poor outcomes. Mean serumMR-proADM values in
healthy individuals measure around 0.33 nmol/L, thus the median level of 1.1 nmol/L observed
in the present study is beyond normal values [23]. This finding may in part reflect hemody-
namic stress among individuals with severe aortic stenosis. However, it was still possible to
Fig 1. Mortality rates of patients receiving TAVR, grouped by upper quartile of MR-proADM and EuroSCORE II. (A) Hazard rates. (B) Cumulative
hazard rates. (C) Cumulative survival probabilities. (D) Hazard ratio (ES II = EuroSCORE II).
doi:10.1371/journal.pone.0143761.g001
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stratify patients according to quartiles of MR-proADM into subgroups with markedly varying
outcomes. This finding aligns well with previous studies in which prototypical biomarkers of
heart failure performed poorly as discriminators of risk in patients with aortic stenosis [29]. By
its stress-responsive expression in many tissues and organ systems [30], MR-proADM appears
Fig 2. Longitudinal trajectories of MR-proADM and CRP at post-interventional day 1–3 following TAVR. (A) Median and interquartile range of
biomarkers in patients after TAVR according to postoperative mortality. (B) Individual trajectories of MR-proADM and CRP with LOWESS smoothing
following TAVR.
doi:10.1371/journal.pone.0143761.g002
Table 6. Reclassification and calibration indices of the MR-proADM-enhancedmodel as compared to commonly used risk schmes (EuroSCORE
II).
Variable Hosmer-
Lemeshow
goodness of ﬁt
(x2, P value)
LRT
(x2, P
value)
IDI
events
(95% CI)
IDI non-
events
(95% CI)
IDI
(95%
CI)
NRI
events
(95% CI)
NRI non-
events
(95% CI)
NRI
(95%
CI)
Risk
category
NRI events
(95% CI)
Risk
category
NRI non-
events (95%
CI)
Risk
category
NRI (95%
CI)
MR-
proADM
nmol/L
5.3, 0.7 29.8,
<0.01
0.24
(0.07–
0.45)
0.03
(0.01–
0.97)
0.27
(0.07–
0.51)
0.29
(-0.19
0.73)
0.60
(0.47–
0.86)
0.89
(0.28–
1.59)
-0.11 (-0.35–
0.54)
0.53 (0.25–
0.87)
0.41 (0.21–
1.13)
Abbreviations: LRT = liklehood ratio test, IDI = integrated discrimination improvement, NRI = net reclassiﬁcation index.
doi:10.1371/journal.pone.0143761.t006
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to be poised well as a multidimensional indicator of poor health and reduced life expectancy in
a heterogenous elderly patient population. In this regard, increased MR-proADM levels ( 1.3
nmol/L) appear to flag the patient as being at risk for a lack of durable benefit following TAVR,
highlighting the value of biomarkers as a companion diagnostic in the decision making process
of whether a patient will benefit from TAVR or not. Future studies are needed to define the
optimal clinical decision criteria based on calculated risk in terms of classifying patients into
clinically meaningful risk categories. In particular, adequately powered studies need to evaluate
the sensitivity and specificity of risk-based thresholds in larger cohorts. The present study pro-
vides a useful starting point for further comparison of MR-proADM-enhanced models with
Fig 3. Predictiveness curves for the two risk models investigated (EuroSCORE II and EuroSCORE II+MR-proADM).Open circles display observed
proportions of death within risk deciles. Left: model based on EuroSCORE II; right: model based on both EuroSCORE II and MR-proADM (both upper
quartile) (ES II = EuroSCORE II).
doi:10.1371/journal.pone.0143761.g003
Fig 4. Overlay of Kaplan-Meier curves and RPmean survival curves in the two prognostic groups (upper and lower quartiles of RP-model
predicted risk). (A) Model for MR-proADM + EuroSCORE II. (B) Model for EuroSCORE II.
doi:10.1371/journal.pone.0143761.g004
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Fig 5. Validation of the RP-derived PI. Solid lines: Kaplan-Meier survival curves in two prognostic
groups (upper and lower quartiles of predicted risk) in the validation cohort.Dashed lines: RP mean
survival functions in the same prognostic groups of the validation cohort by the model fit to the derivation
cohort.
doi:10.1371/journal.pone.0143761.g005
Fig 6. Clinical model enhancement by addition of MR-proADM. Risk assessment plot for the reference
(EuroSCORE II, dashed lines) and biomarker-enhanced (solid line) model for 1-year mortality;
1-specificity versus calculated risk for those with the event and sensitivity versus calculated risk for those
without events are shown.
doi:10.1371/journal.pone.0143761.g006
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commonly used risk scoring algorithms with regard to their ability to improve therapeutic tri-
age of patients according to expected long term benefit. The parametric survival model
employed in this study enabled generation of smooth estimates of the underlying hazard and
survival function. Future studies should incorporate longer timer frames allowing for a better
understanding of vulnerable periods following TAVR in an elderly patient population.
Limitations
The moderate sample size of the study limited the possibility to control for multiple baseline
characteristics as possible confounders of the distribution of MR-proADM. Consequently, ade-
quately powered larger scale studies are needed to confirm our findings. However, the confir-
mation of our results in an independent external patient population adds importantly to the
validity of the conclusions reached. Secondly, although MR-proADM was also analyzed as a
continuous variable, the cut points applied in the study were not a priori specified but based on
calculation of quartiles of MR-proADM upon entry into the study. Future studies are needed
to define the clinical decision tree and optimal cut points that signify a high-risk phenotype in
a heterogeneous elderly patients population awaiting TAVR.
Conclusions
This is the first study on the role of MR-proADM as a companion diagnostic tool for risk strati-
fication of patients undergoing TAVR. Our data support a biomarker-guided strategy for the
evaluation of patients as to their suitability for TAVR with respect to expected long-term
benefit.
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